Evaluation of newer prognostic markers for adult soft tissue sarcomas

Journal of Clinical Oncology

Volumn 15, Issue 10, 1997, Pages 3249-3257

  Levine, Edward A ^a   Holzmayer, Tatyana ^a   Bacus, Sarah ^a   Mechetner, Eugene ^a   Mera, Robertino ^a   Bolliger, Christian ^a   Roninson, Igor B ^a   Das Gupta, Tapas K ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; KI 67 ANTIGEN; MESSENGER RNA; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DNA CONTENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SOFT TISSUE SARCOMA;

EID: 0030928083     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.10.3249     Document Type: Article

References (71)

1. American Joint Committee on Cancer: Manual for Staging of Cancer (ed 4). Philadelphia, PA, Lippincott, 1992
2. Shiu MH, Brennan MF: Surgical Management of Soft Tissue Sarcoma. Philadelphia, PA, Lea & Febiger, 1989
3. Singer S, Corson JM, Demetri GD, et al: Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg 221:185-195, 1995
4. Gaynor JJ, Tan CC, Casper ES, et al: Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: A study of 423 adults. J Clin Oncol 10:1317-1329, 1992
5. Hajdu SI, D'Ambrosio FG: Histopathologic classification of limb sarcomas in relation to prognosis. Surg Oncol Clin North Am 2:509-535, 1993
6. Ueda T, Aozasa K, Tsujimoto M, et al: Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 63:1607-1611, 1989
7. Zehr RJ, Bauer TW, Marks KE, et al: Ki-67 and grading of malignant fibrous histocytomas. Cancer 66:1984-1990, 1990
8. Alvegard TA, Berg NO, Baldetorp B, et al: Cellular DNA content and prognosis of high-grade soft tissue sarcoma: The Scandinavian Sarcoma Group experience. J Clin Oncol 8:538, 1990
9. Bauer HCF, Kreicbergs A, Tribukait B: DNA content prognostic in soft tissue sarcoma: 102 patients followed for 1-10 years. Acta Orthop Scand 62:187, 1991
10. Ferno M, Baldetorp B, Akerman M: Flow cytometric DNA analysis of soft tissue sarcomas: A comparative study of fine needle aspirates and postoperative fresh tissues and archival material. Anal Quant Cytol Histol 12:251, 1990
11. Krekbergs A, Tribukait B, Willems J, et al: DNA flow analysis of soft tissue tumors. Cancer 59:128, 1987
12. Matsuno T, Gebhardt MC, Schiller AL, et al: The use of flow cytometry as a diagnostic aid in the management of soft-tissue tumors. J Bone Joint Surg 70:751, 1988
13. Zapulski MM, Maclorowski Z, Ryan JR, et al: DNA content parameters of paraffin-embedded soft tissue sarcomas: Optimization of retrieval technique and comparison to fresh tissue. Cytometry 14:327-333, 1993
14. Levine EA, Roninson IB, Kim DK, et al: MDR-1 expression in soft tissue sarcoma. Surg Forum 45:503-505, 1994
15. Tawa A, Inoue M, Ishihara S, et al: Increased expression of the multidrug-resistance gene in undifferentiated sarcoma. Cancer 66:1980-1983, 1990
16. Fojo AT, Ueda K, Slamon DJ, et al: Expression of a multidrug-resistance gene in human tumor and tissues. Proc Natl Acad Sci USA 84:265-269, 1987
17. Goldstein LJ, Galski H, Fojo A, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124, 1989
18. Robey-Cafferty SS, Rutledge ML, et al: Expression of a multidrug resistance gene in esophageal adenocarcinoma. Am J Clin Pathol 93:1-7, 1990
19. Wunder JS, Bell RS, Wold L, et al: Expression of the multidrug resistance gene in osteosarcoma: A pilot study. J Orthop Res 11:396-403, 1993
20. Chan HSL, Thorner PS, Haddad G, et al: Immunohistochemical detection of P-glycoprotein: Prognostic correlation of soft tissue sarcoma of childhood. J Clin Oncol 8:689-704, 1990
21. Chan HSL, Haddad G, Thorner PS, et al: P-glycoprotein expression as a predictor of the outcome or therapy for neuroblastoma. N Engl J Med 325:1608-1614, 1991
22. Zapulski MM, Ryan JR, Hussein ME, et al: Systemic adjuvant chemotherapy for soft tissue sarcomas of the extremities. Surg Oncol Clin North Am 2:621-637, 1993
23. Gerdes J, Schwab U, Lemke H, et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20, 1983
24. Pastan I, Gottesman M: Multiple-drug resistance in human cancer. N Engl J Med 316:1388-1393, 1987
25. Gerlach JH, Kartner N, Bell DR, et al: Multidrug resistance. Cancer Surv 5:25-46, 1986
26. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62:385-427, 1993
27. Roninson IB (ed): Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York, NY, Plenum, 1991, pp 189-211
28. Chen C-J, Clark D, Ueda K, et al: Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 265:506-514, 1990
29. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155-199, 1990
30. Antman K, Crowley J, Balcerzak SP, et al: An Intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11:1276-1285, 1993
31. Blum RH: An overview of studies in Adriamycin in the United States. Cancer Chemother Rep 6:247-251, 1975
32. Holzmayer TA, Hilsenbeck S, Von Hoff DD, et al: Clinical correlates of MDR-1 (P-glycoprotein) gene expression in ovarian and small cell lung carcinomas. J Natl Cancer Inst 84:1486-1491, 1992
33. Noonan KE, Beck C, Holzmayer TA, et al: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci 87:7160-7164, 1990
34. Cordon-Cardo C, O'Brien JP, Boccia J, et al: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287, 1990
35. Gerlach JH, Bell DR, Karakousis C, et al: P-glycoprotein in human sarcoma: Evidence for multidrug resistance. J Clin Oncol 5:1452-1460, 1987
36. Roessner A, Ueda Y, Bockhorn-Dworniczak B, et al: Prognostic implication of immunodetection of P-glycoprotein in Ewing's sarcoma. J Cancer Res Clin Oncol 119:185-189, 1993
37. Bacus S, Flowers JL, Bacus JW, et al: The evaluation of estrogen receptor in primary breast carcinoma by computer assisted image analysis. Am J Clin Pathol 90:233-239, 1988
38. Chirgwin JM, Przybyla AE, MacDonald RJ, et al: Isolation of biologically active ribonuclear acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299, 1979
39. Lin RI, Schjeide OA: Micro estimation of RNA by the cupric ion catalyzed orcinol reaction. Anal Biochem 27:473-483, 1969
40. Noonan KE, Roninson IB: mRNA phenotyping by enzymatic amplification of randomly primed cDNA. Nucleic Acids Res 16:10366, 1988
41. 2-microglobulin gene primary structure and definition of the transcriptional unit. J Immunol 139:3132-3138, 1987
42. Chen CJ, Chin JE, Ueda K, et al: Internal duplication and homology with bacterial transport proteins in the mdr-1 (p-glycoprotein) gene from multidrug resistant human cells. Cell 47:381-389, 1986
43. Kwok S, Higuchi R: Avoiding false positives with PCR. Nature 339:237-238, 1989
44. Akiyama S-I, Fojo A, Hanover JA, et al: Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11:117-125, 1985
45. Bacus SS, Goldschmidt R, Chin D, et al: Biological grading of breast cancer using antibodies to proliferating cells and other markers. Am J Pathol 135:783-792, 1989
46. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
47. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
48. Pappo AS, Crist WM, Kuhesch J, et al: Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. J Clin Oncol 11:1901-1905, 1993
49. Kilpatrick SE, Teot LA, Geisinger KR, et al: Relationship of DNA ploidy to histology and prognosis in rhabdomyosarcoma. Comparison of flow cytometry and image analysis. Cancer 74:3227-3233, 1994
50. Scotlandi K, Serra M, Manara C, et al: Clinical relevance of Ki-67 expression in bone tumors. Cancer 75:806-814, 1995
51. Drobnjak M, Latres E, Pollack D, et al: Prognostic implications of p53 overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 86:549-554, 1994
52. De Riese WT, Crabtree WN, Allhoff EP, et al: Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol 11:1804-1808, 1993
53. Hall PA, Richards MA, Gregory WM, et al: The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphoma. J Pathol 154:223-235, 1988
54. Swanson SA, Brooks JJ: Proliferation markers Ki-67 and p105 in soft-tissue lesions. Am J Pathol 137:1491-1500, 1990
55. Yang P, Hirose T, Hasegawa T, et al: Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histocytoma. Cancer 76:618-625, 1995
56. Itsubo M, Ishikawa T, Toda G, et al: Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 73:298-303, 1994
57. Levine EA, Holzmayer TA, Roninson IB, et al: MDR-1 expression in metastatic malignant melanoma. J Surg Res 54:621-624, 1993
58. Schinkel AH, Arceci RJ, Smit JJM, et al: Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein. Int J Cancer 55:478-484, 1993
59. Mechenter EB, Roninson IB: Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 89:5824-5828, 1992
60. Campos L, Guyotat D, Archimbaud E, et al: Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 79:473-476, 1992
61. Schneider J, Rubio M-P, Barbazan M-J, et al: P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 86:850-855, 1994
62. Volm M, Kastel M, Mattern J, et al: Expression of resistance factors (P-glycoprotein, glutathione transferase p, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 71:3981-3987, 1993
63. Baldini N, Scotlandi K, Barbanti-Brodano G, et al: Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380-1385, 1995
64. Chaudhary PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85:632-639, 1993
65. Niimi S, Nakagawa K, Yokata J, et al: Resistance to anticancer drugs in NIH 3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 63:237-241, 1991
66. Chin K-V, Ueda K, Pastan I, et al: Modulation of activity of the promoter of the human MDR-1 gene by Ras and p53. Science 255:459-462, 1992
67. Benchimol S, Ling V: P-glycoprotein and tumor progression. J Natl Cancer Inst 86:814-815, 1994
68. Sikic BI: Modulation of multidrug resistance: At the threshold. J Clin Oncol 9:1629-1635, 1993
69. Pinedo HM, Giaccone G: P-glycoprotein - A marker of cancer cell behavior. N Engl J Med 333:1417-1419, 1995
70. Raderer M, Scheithauer W: Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553-3563, 1993
71. DeZen L, Sommaggio A, d'Amore ESG, et al: Clinical relevance of DNA ploidy and proliferative activity in childhood rhabdomyosarcoma: A retrospective analysis of patients enrolled onto the Italian cooperative rhabdomyosarcoma study RMS88. J Clin Oncol 15:1198-1205, 1997